The Centers for Medicare & Medicaid Services May 7 issued a final rule that implements the standards governing health insurance issuers and the Health Insurance Marketplaces (or “exchanges”) for 2021.

In the rule, CMS finalized the benefit and payment parameters for qualified health plan issuers selling on the exchanges, as well as additional policies intended to lower premiums, promote program integrity, stabilize the individual and small group markets, enhance the consumer experience and reduce regulatory burden.

Also in the rule, CMS finalized value-based insurance design options that QHP issuers can choose to implement; updated how cost sharing calculations will account for drug manufacturer coupons; finalized small updates to medical loss ratio and special enrollment period rules; and increased the annual maximum out-of-pocket spending limits.

CMS did not finalize its proposal to require enrollees with no premium after a premium tax credit is applied to actively re-enroll or face reduced subsidies, consistent with AHA’s comments on the proposed rule.

Download the Special Bulletin for a summary of the key issues.

Related News Articles

Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
States have until Sept. 30 to submit an optional letter of intent to the Centers for Medicare & Medicaid Services indicating they plan to apply to the…
Headline
Ashley Thompson, AHA senior vice president of public policy analysis and development, participated in a panel discussion during Modern Healthcare's Leadership…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…